Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of inborn errors of glycogen metabolism that is clinically and genetically heterogeneous. This group comprises GSD due to liver phosphorylase kinase (PhK) deficiency, GSD due to muscle PhK deficiency and GSD due to liver and muscle PhK deficiency.
Biomarker and diagnostic research for glycogen storage disease IX has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
130 publications have been identified in PubMed for glycogen storage disease IX. Research spans Epidemiology / Natural History (27%), Case Report / Case Series (18%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 35 | 27% |
Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 9:29 PM UTC
European rare disease database
Patient case studies | 24 | 18% |
Research summaries | 18 | 14% |
Clinical study results | 18 | 14% |
Laboratory research | 15 | 12% |
Testing and diagnosis research | 9 | 7% |
New treatment approaches | 9 | 7% |
Other research | 2 | 2% |
Fu S (2026). [PMID: 41757410](https://pubmed.ncbi.nlm.nih.gov/41757410/). *J Comp Eff Res*. [Review / Meta-Analysis]
Ali-Haimoud S (2026). [PMID: 41914518](https://pubmed.ncbi.nlm.nih.gov/41914518/). *Afr J Reprod Health*. [Epidemiology / Natural History]
Lanfranconi F (2026). [PMID: 41725048](https://pubmed.ncbi.nlm.nih.gov/41725048/). *Physiol Rep*. [Basic Science / Preclinical]
Vergès B (2026). [PMID: 41866072](https://pubmed.ncbi.nlm.nih.gov/41866072/). *Ann Endocrinol (Paris)*. [Review / Meta-Analysis]
Yuan C (2026). [PMID: 41861207](https://pubmed.ncbi.nlm.nih.gov/41861207/). *Medicine (Baltimore)*. [Case Report / Case Series]
Maulet T (2026). [PMID: 41785434](https://pubmed.ncbi.nlm.nih.gov/41785434/). *Neurology*. [Epidemiology / Natural History]
Liu N (2026). [PMID: 40884535](https://pubmed.ncbi.nlm.nih.gov/40884535/). *J Magn Reson Imaging*. [Epidemiology / Natural History]
Daghar H (2026). [PMID: 41577969](https://pubmed.ncbi.nlm.nih.gov/41577969/). *Commun Biol*. [Basic Science / Preclinical]
Faraguna MC (2026). [PMID: 41284148](https://pubmed.ncbi.nlm.nih.gov/41284148/). *BioDrugs*. [Gene Therapy / Novel Therapeutics]
Montalvo-Romeral V (2026). [PMID: 41659772](https://pubmed.ncbi.nlm.nih.gov/41659772/). *JHEP Rep*. [Basic Science / Preclinical]